Literature DB >> 23728338

Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression.

G Comito1, E Giannoni1, C P Segura1, P Barcellos-de-Souza1, M R Raspollini2, G Baroni2, M Lanciotti3, S Serni3, P Chiarugi4.   

Abstract

Inflammation is now acknowledged as an hallmark of cancer. Cancer-associated fibroblasts (CAFs) force a malignant cross talk with cancer cells, culminating in their epithelial-mesenchymal transition and achievement of stemness traits. Herein, we demonstrate that stromal tumor-associated cells cooperate to favor malignancy of prostate carcinoma (PCa). Indeed, prostate CAFs are active factors of monocyte recruitment toward tumor cells, mainly acting through stromal-derived growth factor-1 delivery and promote their trans-differentiation toward the M2 macrophage phenotype. The relationship between M2 macrophages and CAFs is reciprocal, as M2 macrophages are able to affect mesenchymal-mesenchymal transition of fibroblasts, leading to their enhanced reactivity. On the other side, PCa cells themselves participate in this cross talk through secretion of monocyte chemotactic protein-1, facilitating monocyte recruitment and again macrophage differentiation and M2 polarization. Finally, this complex interplay among cancer cells, CAFs and M2 macrophages, cooperates in increasing tumor cell motility, ultimately fostering cancer cells escaping from primary tumor and metastatic spread, as well as in activation of endothelial cells and their bone marrow-derived precursors to drive de novo angiogenesis. In keeping with our data obtained in vitro, the analysis of patients affected by prostate cancers at different clinical stages revealed a clear increase in the M2/M1 ratio in correlation with clinical values. These data, coupled with the role of CAFs in carcinoma malignancy to elicit expression of stem-like traits, should focus great interest for innovative strategies aimed at the co-targeting of inflammatory cells and fibroblasts to improve therapeutic efficacy.

Entities:  

Mesh:

Year:  2013        PMID: 23728338     DOI: 10.1038/onc.2013.191

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  165 in total

1.  Epithelial-mesenchymal transition: a new target in anticancer drug discovery.

Authors:  Fabrizio Marcucci; Giorgio Stassi; Ruggero De Maria
Journal:  Nat Rev Drug Discov       Date:  2016-01-29       Impact factor: 84.694

2.  Tissue necrosis and its role in cancer progression.

Authors:  Adi Karsch-Bluman; Ariel Feiglin; Eliran Arbib; Tal Stern; Hila Shoval; Ouri Schwob; Michael Berger; Ofra Benny
Journal:  Oncogene       Date:  2018-11-02       Impact factor: 9.867

Review 3.  Cellular determinants and microenvironmental regulation of prostate cancer metastasis.

Authors:  Kiera Rycaj; Hangwen Li; Jianjun Zhou; Xin Chen; Dean G Tang
Journal:  Semin Cancer Biol       Date:  2017-04-11       Impact factor: 15.707

Review 4.  Role of PKM2 in directing the metabolic fate of glucose in cancer: a potential therapeutic target.

Authors:  Gustav van Niekerk; Anna-Mart Engelbrecht
Journal:  Cell Oncol (Dordr)       Date:  2018-05-24       Impact factor: 6.730

Review 5.  Metabolic implication of tumor:stroma crosstalk in breast cancer.

Authors:  Andrea Morandi; Paola Chiarugi
Journal:  J Mol Med (Berl)       Date:  2014-01-24       Impact factor: 4.599

Review 6.  The interplay between cancer associated fibroblasts and immune cells in the context of radiation therapy.

Authors:  Miles Piper; Adam C Mueller; Sana D Karam
Journal:  Mol Carcinog       Date:  2020-05-04       Impact factor: 4.784

Review 7.  Concise Review: Prostate Cancer Stem Cells: Current Understanding.

Authors:  Sergej Skvortsov; Ira-Ida Skvortsova; Dean G Tang; Anna Dubrovska
Journal:  Stem Cells       Date:  2018-08-27       Impact factor: 6.277

8.  Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation.

Authors:  Manisha Singh; Hiep Khong; Zhimin Dai; Xue-Fei Huang; Jennifer A Wargo; Zachary A Cooper; John P Vasilakos; Patrick Hwu; Willem W Overwijk
Journal:  J Immunol       Date:  2014-09-24       Impact factor: 5.422

9.  Senescent stroma promotes prostate cancer progression: the role of miR-210.

Authors:  Maria Letizia Taddei; Lorenzo Cavallini; Giuseppina Comito; Elisa Giannoni; Marco Folini; Alberto Marini; Paolo Gandellini; Andrea Morandi; Gianfranco Pintus; Maria Rosaria Raspollini; Nadia Zaffaroni; Paola Chiarugi
Journal:  Mol Oncol       Date:  2014-07-21       Impact factor: 6.603

Review 10.  Synergistic immunologic targets for the treatment of prostate cancer.

Authors:  Karen M Doersch; Kelvin A Moses; Warren E Zimmer
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.